Galmed Pharmaceuticals Ltd (NAS:GLMD)

$ 4.2 -0.53 (-11.21%) Market Cap: 6.33 Mil Enterprise Value: -6.27 Mil PE Ratio: 0 PB Ratio: 0.19 GF Score: 36/100

Q4 2021 Galmed Pharmaceuticals Ltd Earnings Call Transcript
May 02, 2022

$219.6 (-26.51%)

Earnings
Q3 2021 Galmed Pharmaceuticals Ltd Earnings Call Transcript
Nov 08, 2021

$538.2 (+6.79%)

Earnings
Q2 2021 Galmed Pharmaceuticals Ltd Earnings Call Transcript
Aug 05, 2021

$514.8 (+4.38%)

Earnings
Q1 2021 Galmed Pharmaceuticals Ltd Earnings Call Transcript
May 13, 2021

$403.2 (-8.20%)

Earnings
Q4 2020 Galmed Pharmaceuticals Ltd Earnings Call Transcript
Mar 18, 2021

$615.6 (-2.01%)

Earnings
Galmed Pharmaceuticals Ltd KOL Symposium and Pipeline Update Transcript
Jan 26, 2021
Q3 2020 Galmed Pharmaceuticals Ltd Earnings Call Transcript
Nov 12, 2020

$570.6 (-5.65%)

Earnings
Q2 2020 Galmed Pharmaceuticals Ltd Earnings Call Transcript
Aug 06, 2020

$829.8 (-7.24%)

Earnings
Q1 2020 Galmed Pharmaceuticals Ltd Earnings Call Transcript
May 14, 2020

$914.4 (+2.21%)

Earnings
Q4 2019 Galmed Pharmaceuticals Ltd Earnings Call Transcript
Mar 12, 2020

$610.2 (-19.48%)

Earnings
Q3 2019 Galmed Pharmaceuticals Ltd Earnings Call Transcript
Nov 06, 2019

$768.6 (-10.11%)

Earnings
Q2 2019 Galmed Pharmaceuticals Ltd Earnings Call Transcript
Aug 05, 2019

Earnings

Galmed Pharmaceuticals Ltd KOL Symposium and Pipeline Update Transcript

Jan 26, 2021 / 04:00PM GMT

Release Date Price: $675.9 (-1.70%)

Transcript

Sara Parigian

LifeSci Advisors, LLC - VP of KOL Strategy & Management

Good afternoon and welcome to the Galmed KOL Symposium and Pipeline Update. (Operator Instructions) As a reminder, this webinar is being recorded, and a replay of the event and the investor deck will be made available on the Galmed website following the conclusion of the event.

I would now like to turn the call over to your host, Allen Baharaff, President and Chief Executive Officer of Galmed Pharmaceuticals. Please go ahead, Allen.

Allen Baharaff

Galmed Pharmaceuticals Ltd. - Co-Founder, President, CEO & Chairman

Thank you, Sara. Good afternoon and welcome to our KOL symposium.

Next slide, please. This is our safe harbor and disclaimer statement.

Next slide, please. Special welcome to our KOLs, Professor Arun Sanyal, Professor of Medicine and Chairman to the Gastroenterology division, the Virginia Commonwealth University and our ARMOR Phase III core principal investigator; Professor Shomron Ben-Horin, Chief and Gastro -- Chief of the Gastroenterology

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.